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Abstract
Background: Pulmonary capillary hemangiomatosis is a rare, vascular obstructive disorder that uniformly causes
pulmonary arterial hypertension. Clinically, pulmonary capillary hemangiomatosis is indistinguishable from primary
pulmonary arterial hypertension and histology is required for definitive diagnosis. The distinctive histologic feature
of pulmonary capillary hemangiomatosis is non-malignant extensive proliferation of capillaries in the alveolar septae.
Vasodilator treatment of humans with primary arterial hypertension due to pulmonary capillary hemangiomatosis can
result in fatal acute pulmonary edema. Computed tomography is thus critical to discern pulmonary capillary
hemangiomatosis from other causes of pulmonary arterial hypertension prior to vasodilator therapy. This is
the first report of a vasoproliferative process resembling pulmonary capillary hemangiomatosis in the feline species.
Case presentation: A 15-year-old, male castrated, domestic shorthair cat presented for persistent labored breathing
presumptively due to congestive heart failure despite treatment with diuretics for 7 days. Echocardiography showed
evidence of hypertrophic cardiomyopathy with severe pulmonary hypertension; however, a normal sized left atrium
was not consistent with congestive heart failure. Thoracic computed tomography was performed and showed
evidence of diffuse ill-defined nodular ground glass opacities, enlarged pulmonary arteries, and filling defects
consistent with pulmonary thromboembolism. The cat acutely decompensated after a single dose of sildenafil
and was euthanized. Histopathology of the lungs showed severe multifocal alveolar capillary proliferation with
respiratory bronchiolar infiltration, marked type II pneumocyte hyperplasia and multifocal pulmonary arterial thrombosis.
Conclusion: This is the first description in a cat of a vasoproliferative disorder resembling pulmonary capillary
hemangiomatosis complicated by multifocal pulmonary arterial thrombosis. Inspiratory and expiratory ventilator-driven
breath holds with angiography revealed lesions predominantly characterized by ground glass opacification and
vascular filling defects with absence of air trapping. The results from this report suggest that, as in humans, the cat can
develop a pulmonary capillary hemangiomatosis-like disease in which vasodilator therapy to address pulmonary
hypertension may lead to fatal pulmonary edema.
Keywords: Pulmonary hypertension, Pulmonary thromboembolism, Computed tomography, Lung, Pulmonary vascular
disease, Feline, Ground glass opacity, Pulmonary veno-occlusive disease, Angiography, Animal model
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Background
Pulmonary capillary hemangiomatosis (PCH) is a rare,
idiopathic vascular disease that uniformly causes pulmon-
ary arterial hypertension (PAH) [1]. It was first described
in humans in 1978 as researchers observed atypical prolif-
eration of capillary-like channels in lung tissue that
appeared to be angiomatous growths [1]. The distinctive
histologic feature of PCH is the proliferation of capillaries
in the pulmonary parenchyma [1, 2]. Additional important
features include evidence of invasion by the capillaries
into one or more of the pulmonary veins and arteries,
alveolar walls and alveolar space, interlobular fibrous
septa, and bronchioles [2]. Cytologic atypia and mitoses
are absent in PCH lesions [1]. There have been under 100
cases reported in humans in the literature [3]. PCH as a
feature of pulmonary venoocclusive disease (PVOD), an
obstructive disorder affecting the post-capillary (venous)
pulmonary vasculature that has been reported in humans
[4] and dogs [5]. To the author’s knowledge PCH has not
been described in the cat.
The pathogenesis of PCH is poorly understood and is
likely multifactorial. In humans, PCH has been described
in association with aortic stenosis [6], Kartagener
syndrome [7], systemic lupus erythematous [8], sclero-
derma [9], Takayasu’s arteritis [10], hypertrophic cardio-
myopathy [11] and neoplasia [12, 13]. Mutations in the
eukaryotic translation initiation factor 2 alpha kinase 4
(EIF2AK4) gene are a risk factor in the development of
PCH [14]. It has also been proposed that PCH is not a
separate disease, but rather represents a secondary
angioproliferative response to pulmonary venous hyper-
tension as seen in PVOD [4].
The current clinical classification of PH in people has
been categorized in five groups of disorders: pulmonary
arterial hypertension (Group 1), PVOD and/or PCH
(Group 1’), persistent pulmonary hypertension of the
newborn (Group 1”), pulmonary hypertension due to left
heart disease (Group 2), pulmonary hypertension due to
chronic lung diseases and/or hypoxia (Group 3), chronic
thromboembolic pulmonary hypertension (Group 4),
and pulmonary hypertension due to unclear multifactor-
ial mechanisms (Group 5) [15]. There is a paucity of
information regarding PH in cats, mainly being limited
to case reports and small case series. Our proposed
adaptation of the classification system used in people
with PAH to cats based on the available literature is
shown in Table 1 [16–38].
The prognosis for PCH in humans is poor, and without
lung transplant ultimately fatal. The median survival is ap-
proximately 3 years after onset of clinical signs [1, 39].
The only definitive treatment is lung transplantation,
though some therapies (i.e. imatinib [40, 41], doxycycline
[42], interferon [alpha]-2a [43]) have been shown to im-
prove quality of life and survival time. Clinical signs
Table 1 Feline Classification of Pulmonary Hypertension a
1. Pulmonary arterial hypertension
1.1 Idiopathic PAH (NR)
1.2 Heritable PAH (NR)
1.3 Drug and toxin induced (NR)
1.4 Associated with:
1.4.1 Connective tissue disease (NR)
1.4.2 Immunodeficiency virus (FIV) infection (NR)
1.4.3 Portal hypertension (NR)
1.4.4 Congenital heart diseases: Patent ductus arteriosus [16–18];
Atrial septal defect [19]; Partial anomalous pulmonary
venous connection [20];Double-outlet right atrium [37];
Ventricular septal defect [38]
1.4.5 Schistosomiasis (NR)
1’ Pulmonary veno-occlusive disease and/or pulmonary capillary
hemangiomatosis
Current report
1” Persistent pulmonary hypertension of the newborn (NR)
2. Pulmonary hypertension due to left heart disease
2.1 Left ventricular systolic dysfunction (NR)
2.2 Left ventricular diastolic dysfunction (NR)
2.3 Valvular disease (NR)
2.4 Congenital/acquired left heart inflow/outflow tract
obstruction and congenital cardiomyopathies: Supra
valvular mitral stenosis [21–23]; Cor triatriatum [24–28]
3. Pulmonary hypertension due to lung diseases and/or hypoxia
3.1 Chronic obstructive pulmonary disease
Nasopharyngeal polyp induced hypoxia [30]
3.2 Interstitial lung disease
Interstitial pulmonary fibrosis [29]
3.3 Other pulmonary diseases with mixed restrictive and
obstructive pattern (NR)
3.4 Sleep-disordered breathing (NR)
3.5 Alveolar hypoventilation disorders (NR)
3.6 Chronic exposure to high altitude (NR)
3.7 Developmental lung diseases (NR)
4. Chronic thromboembolic pulmonary hypertension
Pulmonary thromboembolism [31–33]
5. Pulmonary hypertension with unclear multifactorial mechanisms
5.1 Hematologic disorders: chronic hemolytic anemia (NR),
myeloproliferative disorders (NR), splenectomy (NR)
5.2 Systemic disorders: sarcoidosis (NR), pulmonary
histiocytosis (NR), lymphangiomyomatosis (NR)
5.3 Metabolic disorders: glycogen storage disease (NR),
Gaucher disease (NR), thyroid disorders (NR)
5.4 Others: tumoral obstruction (NR), fibrosing mediastinitis
(NR), chronic renal failure (NR), segmental PH (NR)
5.4.1
(proposed in cats)
Dirofilaria immitis [34, 35]; Aelurostrongylus abstrusus [36]
NR not reported, PAH pulmonary arterial hypertension, FIV feline
immunodeficiency virus
a Adapted for the cat from the Human 5th World Symposium on
Pulmonary Hypertension Nice, France 2013
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associated with PCH include progressive dyspnea, exer-
tional fatigue, syncope, and sometimes a chronic cough
[1] and are frequently seen in other forms of PAH. The
commonality in presenting clinical signs makes differenti-
ating PCH from other forms of PAH challenging. While
difficult, this distinction is essential because conventional
treatment with vasodilators for PAH is contraindicated in
patients with PCH as it can result in fatal pulmonary
edema [44–46].
Histopathologic examination of lung tissue for defini-
tive confirmation of PCH requires invasive sampling and
can be contraindicated depending on patient stability. In
cats, high resolution computed tomography (HRCT) has
been used to help identify interstitial lung diseases
including interstitial pulmonary fibrosis [29], alveolar
filling disorders such as pulmonary alveolar proteinosis
[47] and vascular disease like pulmonary thromboemboli
[48] and partial anomalous pulmonary venous connec-
tion [49]. In humans, HRCT has been used to differenti-
ate PAH from PCH [50]. Main pulmonary arterial
enlargement and diffuse ill-defined centrilobular nodules
of ground glass opacity are commonly seen in people
with PCH but the latter are not seen with PAH [1, 51].
With increased recognition of other causes of pulmonary
hypertension, and in particular PAH in the cat, future
use of HRCT may be an invaluable diagnostic for pul-
monary hypertension in Groups 1, 3, and 4 (see Table 1).
Importantly, prior to initiating vasodilator therapy,
HRCT may allow differentiation of PCH and PVOD from
PAH in veterinary species as it does in humans [1, 51].
Case presentation
A 15-year old male castrated domestic shorthair cat was
referred to the University of Missouri Veterinary Health
Center for evaluation of presumed congestive heart fail-
ure. The cat was clinically healthy until the age of 14
years, when he experienced an episode of abrupt, severe
fatigue while playing with a toy. The cat did not lose
consciousness and recovered quickly with no medical
intervention. The cat remained clinically normal for
approximately a year, at which time he suffered a brief
syncopal event while playing with a toy. The cat was
evaluated by the referring veterinarian and treated with
furosemidea (2.2 mg/kg, PO, q12 hr) for presumptive
congestive heart failure. The cat subsequently developed
a decreased appetite and an increase in respiratory effort
and rate until presentation 7 days later.
The cat was the only animal in the house and never
ventured outdoors. The owner did not have any known
potentially hazardous hobbies (i.e. painting, crafts, fur-
niture restoration). There was no known exposure to
noxious/irritant inhalational agents (i.e. cigarette smoke,
air-freshener, incense, etc.). The cat was up to date on vac-
cinations as well as heartworm and flea preventative.
At presentation the cat was bright, alert, and respon-
sive. He showed tachypnea (60 breaths/minute) with in-
creased inspiratory effort. He was mildly hypothermic
(rectal temperature 99°F), and was approximately 5%
dehydrated. His heart rate was 160 beats/minute with an
occasional irregular rhythm that resulted in pulse defi-
cits. Thoracic auscultation revealed a grade III/VI left
parasternal systolic murmur and normal respiratory
sounds. The hair coat appeared dull and unkempt. The
cat weighed 5.6 kg (12 lbs). The rest of the physical
examination was unremarkable.
Thoracic radiographs showed cardiomegaly and mild
enlargement of the right pulmonary artery. The left pul-
monary was larger than the left pulmonary vein proxim-
ally but became ill defined at the level of the 9th rib. In
Fig. 1 Orthogonal radiographic projections of a 15-year-old cat with
pulmonary capillary hemangiomatosis. a Left lateral projection showing
mild cardiomegaly, the cardiac silhouette occupying almost three
intercostal spaces. The caudal pulmonary vessels are ill-defined
and less opaque than normally expected (arrows). A mild focal
unstructured interstitial pattern (*) is seen in the ventral aspect
of the caudal lung field, partly overlying the caudal vena cava
(CVC). b Dorsoventral projection demonstrating mild cardiomegaly with
the cardiac silhouette occupying more than 50% of the hemithorax
measured at the ninth ribs. The caudal lobar pulmonary arteries are
larger than the corresponding pulmonary veins measured at the ninth
ribs (right: between arrows, left: between arrowheads). The left caudal
lobar pulmonary artery abruptly becomes less distinct caudal to the
ninth rib. Multifocal patchy areas of unstructured interstitial pattern with
ill-defined borders (*) are seen in the right and left caudal lung lobes
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addition, there was a multi-focal interstitial pattern
within the ventral aspect of caudal lung lobes (Fig. 1).
Serum antigen for feline heartworm and feline leukemia
virus and serum antibodies for feline immunodeficiency
virus were not detected.b Serum total T4 concentration
was normal (2.3ug/dL; reference interval, 0.8 to 4.0 ug/
dL). Serum biochemical parameters outside of the ref-
erence interval were glucose (178 mg/dL; reference
interval 52 to 153 mg/dL), blood urea nitrogen (59
mg/dL; reference interval 17 to 35 mg/dL), creatinine (3.1
mg/dl; reference interval 0.5 to 2.2 mg/dL), and potassium
(2.5 mEq/L; reference interval 3.0 to 4.7 mEq/L).
Hematologic abnormalities were neutrophilia (13.34 ×
103/uL; reference interval, 2.5 to 12.5 × 103/uL), lympho-
penia (1.48 × 103/uL; reference interval, 1.5 to 7.0 × 103/
uL), and monocytosis (1.15 × 103/uL; reference interval, 0
to 0.85 × 103/uL). A urinalysis obtained via cystocentesis
showed a urine specific gravity of 1.019. The hematologic
abnormalities and mild hyperglycemia were believed to be
secondary to stress. The hypokalemia, azotemia and min-
imally concentrated urine were presumed to be secondary
to diuretic therapy; however chronic kidney disease could
not be ruled out as there was no serum biochemical panel
or urinalysis available for comparison prior to initiation of
diuretic therapy. Abdominal ultrasonography was
unremarkable.
The echocardiogram revealed significant left ventricu-
lar hypertrophy, moderate right ventricular hypertrophy
and normal left atrial dimensions (Fig. 2a-b). Color Dop-
pler Echocardiography showed a moderate amount of
tricuspid regurgitation (Fig. 3a). Continuous-wave Dop-
pler assessment of the peak tricuspid regurgitation was
measured at 4.2m/sec resulting in a tricuspid regurgitation
pressure gradient between the right atrium and right ven-
tricle of 70.2mmHg (calculated using the modified
Bernoulli equation, Δp = 4V2)(Fig. 3b). Due to the tricus-
pid regurgitation jet direction the true peak velocity and
with that the pressure gradient may have been underesti-
mated. By adding the estimated right atrial pressure,
75.2mmHg was calculated as the systolic pulmonary artery
pressure [52]. Due to the lack of a pulmonary arterial
pressure classification scheme specific for cats, this infor-
mation was extrapolated from the dog [53]. The cat was
subsequently diagnosed with hypertrophic obstructive car-
diomyopathy and moderate to severe pulmonary arterial
hypertension (PAH). Given the normal left atrial size it
was concluded that congestive heart failure was unlikely.
Based on echocardiography a primary cause for PAH was
not identified. There was no evidence of structures con-
sistent with adult D. immitis or thromboemboli in the
main pulmonary artery or in close proximity to the bifur-
cation. However, their presence could not be excluded fur-
ther distally.
The cat was housed in an oxygen chamber and treated
overnight with 40% inhalational oxygen and intravenous
fluids. While being treated with supplemental oxygen, the
cat’s respiratory effort normalized and rate decreased.
The following day the cat had thoracic computed tom-
ography (CT, 64-detector row Toshiba Aquilion, Toshiba
America Medical Systems, Tustin, CA) to determine an
identifiable underlying cause of PH (i.e. primary lung dis-
ease or thromboemboli). The cat was premedicated with
butorphanolb (0.5 mg/kg IV). Following premedication,
general anesthesia was induced with alfaxalonec (1.8 mg/
kg IV) and maintained with intravenous alfaxalone (0.2
mg/kg/min). The cat was intubated and mechanically ven-
tilated (Engstrom Carestation ventilator, GE Healthcare).
The ventilator settings included volume-controlled venti-
lation with an inspired oxygen concentration of 40%, tidal
volume 10 mls/kg, respiratory rate 10 breaths/minute, and
Fig. 2 Tricuspid regurgitation. Color Doppler image of tricuspid regurgitation (a) and Continuous Doppler (CW) image (b) from the left apical 4-
chamber view optimized for the right ventricle. Tricuspid regurgitation approximates 4.2m/sec, indicating a peak tricuspid regurgitation pressure
gradient of approximately 70mmHg (moderate pulmonary hypertension). LA—left atrium, LV—left ventricle, RA—right atrium, RV—right ventricle,
TR—tricuspid regurgitation (orange arrow)
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positive end-expiratory pressure (PEEP) 5 cm H20. In-
spiratory and expiratory breath holds were ventilator-
assisted and performed in tandem with CT scans; PEEP
was set to 0 cm H20 for the expiratory breath hold.
Contiguous 1–2 mm transverse images, pre-and post-
contrast administration, were obtained from the level of
C6 to L2 with the cat in sternal recumbency. Both inspira-
tory and expiratory sequences were performed as well as
arterial, venous, and delayed phases. Iodinated contrastd
was injected at 3 ml/s velocity with a total volume of 12
ml (2.1 mg/kg). The sure-start feature of the CT scanner
was used to automatically start image acquisition when
the threshold of 180 Hounsfield units (HU) inside the
aortic-arch was reached thus defining the arterial phase.
The image acquisition of the venous phase started auto-
matically following termination of the arterial phase. The
images acquired in the delayed phase were obtained
exactly 2 min following the start of the arterial phase. On
the pre-contrast inspiratory sequence, there were multiple
patchy areas of ground glass opacification in the lung
lobes especially in the cranial lobes that were of similar
size and equally distant from each other (Fig. 4a). The
most peripheral opacities were all at the same distance
from the pleural surface. Ground glass opacification was
also seen in the transition between areas of consolidation
and normal lung attenuation in the ventral aspects of the
lungs bilaterally sparing only the most cranial and most
caudal portions of the lungs (Fig. 4b-c). The left and right
caudal lobar pulmonary arteries were enlarged, being lar-
ger than the corresponding vein (Fig. 4c). In the post-
contrast inspiratory venous sequence, the pulmonary
trunk was subjectively enlarged (1.11 cm vs. 0.929 cm as-
cending aorta), the ascending aorta was displaced to the
right by the enlarged right ventricular outflow tract/
Fig. 4 Inspiratory breath-hold transverse computed tomographic images of a 15-year-old cat with pulmonary capillary hemangiomatosis. a Multiple small
ground glass opacities are seen in the cranial part of the left cranial lung lobe (arrowheads). b Patchy areas of ground glass opacification appearing as
nodular in some areas (arrowheads) progressing towards consolidation medially in the cranial part of the left cranial lung lobe. Hazy ground glass opaci-
fication is also present in the ventral aspect of the right cranial lung lobe (arrows). c Ground glass opacification is noted along the ventral
margin of the left caudal lung lobe (arrowheads). The fissure line at the intersection of the right caudal and right middle lung lobes is thickened and irregu-
lar (white arrows). Subpleural thickening is also observed in the right middle lung lobe (black arrow). The left (LCPa) and right (RCPa) caudal lobar pulmonary
arteries are larger than their counterpart pulmonary veins (PV)
Fig. 3 Turbulent flow in the left ventricular outflow tract. Color Doppler image (a) and Continuous Doppler image (b) both acquired from the left
apical 5-chamber view. Note the acceleration of LVOT flow in end-systole. LA—left atrium, LV—left ventricle, RA—right atrium, RV—right ventricle,
LVOT—left ventricular outflow tract (orange arrow)
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pulmonary trunk (Fig. 5a). The post-contrast arterial
phase showed the presence of iodinated contrast medium
in the pulmonary trunk, left and right pulmonary arteries
(Fig. 5a) and the proximal aspect of the caudal lobar pul-
monary arteries (Fig. 5b). Starting at the level of the 6th
ribs on the left (Fig. 5c) and of the 7th ribs on the right
(Fig. 5d), both caudal lobar pulmonary arteries
demonstrate a major filling defect occupying the entire
lumen of the artery. The lack of contrast medium in the
caudal lobar pulmonary arteries is well illustrated by the
abrupt termination of these arteries in relation to the pul-
monary trunk and thoracic aorta on the three-
dimensional (3D) volume rendering image (Fig. 5e). 3D
Maximum Intensity Projection tool available on the CT
Fig. 5 Pulmonary arterial enlargement and thromboembolism in a 15-year-old cat with pulmonary capillary hemangiomatosis. a-d Transverse
post-contrast CT images extending from the level of the pulmonary trunk to the level of T9. a The pulmonary trunk (PT) is enlarged displacing
the aorta (Ao) to the right. The pulmonary trunk as well as the left (LPa) and right (RPa) pulmonary arteries are filled with iodinated contrast
medium. b After their entry into the hilus of the lungs and division of the first branches, the right and left pulmonary arteries now becoming the
caudal lobar pulmonary arteries (LCPa, RCPa) still present good filling of the entire lumen of the arteries with contrast medium. c After giving off
a branch to the caudal segment of the left cranial lung lobe, the left caudal lobar pulmonary artery (LCPa) presents a large filling defect (*) encompassing
the entire lumen of the vessel while no filling defect is identified in the right caudal lobar pulmonary artery (RCPa) at this level (8th thoracic vertebra). d
After giving off a branch to the ventral aspect of the right caudal lung lobe, a large filling defect (*) involving the entire lumen of the
RCPa is seen. e Dorsal projection of the heart and great vessels obtained using a three-dimensional (3D) volume rendering application tool of the CT
workstation based on volume data from the post-contrast arterial phase. The lack of enhancement due to the absence of contrast medium first in the
LCPa followed approximately 1 cm caudally by the right (RCPa) resulted in an abrupt termination of those vessels instead of a normal tapering towards
the periphery of the lung lobes. Horizontal (f) and sagittal (G-H) post-contrast 3D Maximum Intensity Projection images of the left (g) and right (h) caudal
lobar pulmonary arteries illustrating the location of the filling defects in relation to the longitudinal path of these vessels. On the left side, the artery (LCPa)
abruptly lacks contrast enhancement (*) starting between the 6th (Rib6) and 7th ribs (Rib7) and throughout the caudal extent of the vessel. On the right
side, the lack of contrast enhancement in the artery starts just caudal to the 7th rib and over a length of 4 mm, a filling defect (*) encompassing the entire
lumen and throughout the remainder of the artery is illustrated
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workstation was used to elongate each artery in the hori-
zontal (Fig. 5f) and sagittal (Fig. 5g-h) planes providing ex-
cellent visualization of the filling defects in relation to the
length of each artery.
Following the CT, the cat was maintained in a light
plane of anesthesia with 5 to 6 cm H20 PEEP for an add-
itional hour until he was able to maintain an oxygen
hemoglobin-saturation above 95% without PEEP. The
cat then recovered in an oxygen chamber providing 40%
inhalational oxygen. The cat continued to show tachyp-
nea, maintained oxygen enriched hemoglobin-saturations
of 90 to 95%, and had clear lung sounds on thoracic
auscultation.
Based on diagnostics performed at that time it was sus-
pected the cat had a significant pulmonary vasculopathy
that resulted in PAH. The etiology of the vasculopathy
was unknown at that time but suspected secondary to
thromboembolic disease as well as uncharacterized
primary lung disease. The cat was treated with one dose
of sildenafild (0.9mg/kg, PO). Approximately 45 min
following administration of sildenafil the cat developed
respiratory distress. His respiratory rate increased to 80
breaths/min, he assumed an orthopneic posture, and was
breathing with an open mouth. On thoracic auscultation
the cat had harsh, loud crackles in all lung fields.
Because of the progressively worsening respiratory dis-
tress as well as the grave prognosis, the owner elected
euthanasia. Immediately after euthanasia the lungs
were removed with owner consent and fixed for
histopathology. In an effort to prevent the collapse,
deflation, and disruption of lung structures and to
avoid fixation artifacts, each lung lobe was inflation-
fixed with 10% formalin [54]. Each lobar bronchus
was cannulated with a 3 French red rubber catheter
and fixed with a ligature. The lungs were inflated via
the cannula by gentle infusion of 10% formalin. After
each lobe was sufficiently inflated, the lobar bronchus
was tied off with a ligature and the lungs were placed
in jars containing 10% formalin (ratio at least 1 part
tissue to 9 parts formalin).
In the subgross fixed lung lobes multifocal sharply
demarcated dark red foci were evident within the lung
parenchyma (Fig. 6). Histopathology of these regions
were characterized by severe multifocal alveolar capillary
proliferation (Figs. 7, 8 and 9). Foci of infiltration of re-
spiratory bronchioles was frequent and marked type II
pneumocyte hyperplasia was present in the remodeled
lung. In addition, there was moderate focally extensive
Fig. 6 Subgross fixed lung lobes obtained post-mortem in a 15-year-old
cat with pulmonary capillary hemangiomatosis. Sharply demarcated dark
red foci indicative of the vascular lesions were evident within the lung
parenchyma adjacent to more normal (black arrow) regions of fixed lung
Fig. 7 Lung histopathology in a cat with PCH-like lung disease. The
alveolar parenchyma in foci of affected lung is comprised of numerous
capillaries that obscure the normal alveolar architecture and surround
and infiltrate into bronchioles (br). Hematoxylin-eosin stain
Fig. 8 Lung histopathology in a cat with PCH-like lung disease. Capillary
profiles (arrowheads) are present between and surrounding the bundles
of smooth muscle of a respiratory bronchiole. Hematoxylin-eosin stain
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alveolar congestion with intra-alveolar hemorrhage and
fibrin. Furthermore, there was evidence of multifocal
pulmonary arterial thrombosis and alveolar carcinomas.
The apparent capillary proliferation with infiltration
of respiratory bronchioles is suggestive of PCH. Al-
though PCH often occurs along with PVOD, there
was no evidence of PVOD in this cat. The epithelial
neoplasms were considered to be incidental findings
in this case.
Given the timing of the sildenafil to the cat’s acute re-
spiratory decompensation (45 min prior) it is suspected
that arteriolar dilation with a fixed capillary obstructive
lesion led to flooding of the alveoli from increases in
hydrostatic pressure. In humans with post-capillary PAH
(i.e. PCH and PVOD) treatment with vasodilators can
result in a florid and fatal pulmonary edema. It is also
possible the cat’s abrupt respiratory decline included
additional acute pulmonary thromboemboli; anaphyl-
actic response to the compounded sildenafil or the onset
of acute respiratory distress syndrome were not sup-
ported by histopathologic findings.
The cause for thromboembolic disease was not deter-
mined but could have been secondary to cardiac disease.
Interestingly, a recent report evaluating the microcircula-
tion in people with chronic thromboembolic pulmonary
hypertension found a strong association with capillary
hemangiomatosis-like lesions [55].
Discussion and conclusions
Pulmonary capillary hemangiomatosis is a rare, idio-
pathic angioproliferative disease that results in PAH [1].
The unique histologic feature of PCH is the proliferation
of capillaries in the pulmonary parenchyma as well as
evidence of invasion by the capillaries into one or more
of the pulmonary veins, arteries, alveolar walls, alveolar
space, interlobular fibrous septa, and bronchioles [2].
Histologic evaluation of lung parenchyma from the cat
in this report revealed severe multifocal alveolar capillary
proliferation with infiltration of respiratory bronchioles
suggestive of PCH. The pathogenesis of PCH is poorly
understood and is likely multifactorial. In humans, PCH
has been described in association with several disease
processes includingaortic stenosis, Kartagener syndrome,
systemic lupus erythematous, scleroderma, Takayasu’s
arteritis, hypertropic cardiomyopathy and neoplasia
[6–13]. Echocardiographic evaluation of the cat re-
ported here revealed significant left ventricular hyper-
trophy and normal left atrial dimensions. In humans, it
is postulated that long standing chronic passive conges-
tion of the lung as is seen with hypertrophic cardiomyop-
athy results in development of PCH [11]. The normal left
atrial dimensions in this cat make chronic pulmonary ven-
ous congestion unlikely. It has also been proposed that
PCH is not a separate disease, but rather represents a sec-
ondary angioproliferative response to pulmonary venous
hypertension as seen in PVOD [4]. However, there was no
evidence of PVOD in this cat. In humans, mutations in
the EIF2AK4 gene are a risk factor in the development of
PCH [14]. Future studies investigating the aforementioned
EIF2AK4 gene mutation are needed to establish this asso-
ciation in dogs and cats with PCH.
Pulmonary hypertension is a syndrome characterized
by altered blood flow resulting in elevated pulmonary ar-
terial pressures. In veterinary medicine, PH is classified
based on the origin of altered blood flow, that is, pre-
capillary (pulmonary arterial hypertension) or post-
capillary (pulmonary venous hypertension [56]. The clin-
ical picture was complicated by pulmonary thrombo-
embolism, which also contributed to PH. Thus the PH
identified in the cat described in this report would likely
be classified as both Group 1’ and Group 4 (Table 1).
In humans, clinical signs associated with PCH include
progressive dyspnea, exertional fatigue, syncope, and
sometimes a chronic cough [1] and are frequently seen
in other forms of PAH. The commonality in presenting
clinical signs makes differentiating PCH from other
forms of PAH challenging. While difficult, this distinc-
tion is essential because conventional treatment with va-
sodilators for PAH is contraindicated in patients with
PCH as it can result in fatal pulmonary edema [44–46].
It is currently recommended that patients with pre-
sumed primary pulmonary hypertension undergo a
HRCT examination before initiation of vasodilator ther-
apy [1]. The CT in this case corroborates common CT
findings in humans with PCH; diffuse, ill-defined nodu-
lar ground glass opacities and enlarged pulmonary
Fig. 9 Lung immunohistochemistry for expression of the endothelial
cell surface antigen CD31 in a cat with PCH-like disease. Antibody
against CD31 identifies capillary endothelial cells infiltrating around
bronchiolar smooth muscle (arrowhead) as well as highlighting
the increased numbers of capillaries within the surrounding alveolar
parenchyma. Immunohistochemistry, diaminobenzidine chromagen
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arteries. Given the timing of the sildenafil to the cat’s
acute respiratory decompensation (45 min prior) it is
suspected that arteriolar dilation with a fixed capillary
obstructive lesion led to flooding of the alveoli from in-
creases in hydrostatic pressure.
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